Genenta Science (NASDAQ:GNTA) vs. Biogen (NASDAQ:BIIB) Head to Head Contrast

Biogen (NASDAQ:BIIB) and Genenta Science (NASDAQ:GNTA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Valuation & Earnings

This table compares Biogen and Genenta Science”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89 billion	3.23	$1.29 billion	$9.32	23.19
Genenta Science	N/A	N/A	-$7.39 million	N/A	N/A

Biogen has higher revenue and earnings than Genenta Science.

Institutional & Insider Ownership

87.9% of Biogen shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Biogen and Genenta Science’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Genenta Science	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for Biogen and Genenta Science, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2	12	16	1	2.52
Genenta Science	1	0	0	0	1.00

Biogen presently has a consensus target price of $217.41, indicating a potential upside of 0.60%. Given Biogen’s stronger consensus rating and higher probable upside, research analysts clearly believe Biogen is more favorable than Genenta Science.

Volatility and Risk

Biogen has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Summary

Biogen beats Genenta Science on 10 of the 12 factors compared between the two stocks.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.